Buscar en
Revista Colombiana de Reumatología (English Edition)
Toda la web
Inicio Revista Colombiana de Reumatología (English Edition) B-lymphocyte hyperactivation and autoantibody production in thepathophysiology o...
Journal Information
Vol. 27. Issue 1.
Pages 68-70 (January - March 2020)
Vol. 27. Issue 1.
Pages 68-70 (January - March 2020)
Letter to the Editor
DOI: 10.1016/j.rcreue.2019.03.004
Full text access
B-lymphocyte hyperactivation and autoantibody production in thepathophysiology of cutaneous systemic sclerosis
Hiperactivación del linfocito B y producción de los autoanticuerpos anticentrómero, antitopoisomerasa-I, anti-ARNPol-III en lafisiopatología de la esclerosis sistémica cutánea
Visits
...
Diana Hernández-Flóreza,b, Julia Martínez-Barrioa,b, Francisco Javier López-Longoa,b, Lara Valora,b,c,
Corresponding author
a Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b Instituto de Investigación Biomédica, Hospital Gregorio Marañón, Madrid, Spain
c Rheumatology and Immunology Department, Friedrich-Alexander University Erlangen-Nürnberg, Alemania, Internistisches Zentrum (INZ), Erlangen, Germany
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
Dear Editor:

Cutaneous systemic sclerosis (cSSc) is an autoimmune chronic connective tissue disorder, characterized by microvascular lesions, collagen deposition, and skin and visceral fibrosis including: GI tract, lungs, heart, and kidneys. The detection of circulating autoantibodies (AAb) against antinuclear antibodies (ANA) is important in the diagnosis of the disease and of its clinical presentations - diffuse and localized cSSc.

Notwithstanding the fact that these AAbs participate in the pathophysiology of cSSc, the specific mechanisms that promote the deregulation of the immune system have not been described. It is currently said that: 1) fibrosis is promoted by hyperactive autoantibody producing B lymphocytes, the maturation of fibroblasts, or the inhibition of the degradation of the extracellular matrix, in addition to vasoconstriction and obliterative vasculopathy events; 2) B-lymphocytes promote fibrosis through direct cell contact of fibroblasts and dendritic cells; 3) the reduction of B and T lymphocytes with a regulatory profile, favors the development of tissue fibrosis; 4) Th2 type T lymphocytes produce profibrotic interleukins IL-4 and IL-13, which induce the maturation of dendritic cells and reinforce this profibrotic microenvironment; and 5) the upregulation interferon regulatory genes, induces tissue fibrosis (Fig.1).1–3

Fig. 1.

cSSc etiopathological events, IF patterns, and production of autoantibodies: anticentromere, antitopoisomerase-I, and anti-ARNPol-III.

AAb: autoantibodies; DC: denditric cell; SRC: scleroderma renal crisis; GAVE: gastric antral vascular ectasia; PAH: pulmonary arterial hypertension; IF: immunofluorescence; IFN: interferon; IL: interleukin; BL: B lymphocyte; TL: T lymphocyte; Reg: regulator.

(0.5MB).

The clinical (Raynaud’s phenomenon), histological (microvasculopathy), cellular (apoptosis of the endothelial cells) o autoimmune (development of AAb) events may present years before the manifestation of cutaneous fibrosis.1,2 Between 80–98 % of the patients with AAb exhibit one or several of these patterns of immunofluorescence in the ANA test: centromeric, nucleolar or nuclear fine speckled. It has been noted that these AAb are specifically targeted against centromeric proteins (anticentromere), enzymes such as topoisomerase-I (anti-Scl-70) or enzymes responsible for the transcription of DNA into RNA, such as the nucleotidyltransferase polymerase enzyme of the ribonucleic III acid (anti-ARN Pol-III). Other AAb that may develop, though less frequently, are the so called anti-ribonucleoproteins Th/To, anti-PM-Scl and anti-fibrillarin (U3-RNP).4–7

The importance of such specificity is due to the fact that the frequency of each one of these AAb varies depending on ethnicity and on the geographical background of patients; they have also been associated with different clinical profiles and do not usually coexist in the same patient, or change over the course of the disease. For all of these reasons, their identification at the time of making a diagnosis is extremely valuable to predict which organs will be affected, and the clinical evolution of our patients.

The antitopoisomerase and anticentromere antibodies are associated with diffuse cSSc and localized cSSc, respectively. Anti-Th/To, anti-PM-Scl and antifibrillarin antibodies have been identified in patients with 1) fibrosis and pulmonary hypertension or polymyositis, 2) Systemic Lupus Erythematous, and 3) overlap syndrome, respectively.6,8 Lazzaroni et al., in study promoted by European Scleroderma Trials and Research have shown that the scleroderma renal crisis, gastric antral vascular ectasia, the rapid progression of the skin thickness, pulmonary arterial hypertension and neoplasms, are all independent clinical characteristics associated with the presence of anti-ARNPol-III.9 The significance of these associations has led to the inclusion of anti-ARNPol-III among the most recent criteria for the classification of cSSc, developed by an expert consensus of the American College of Rheumatology and the European League against Rheumatism.10 Therefore, in the usual clinical practice, in addition to the determination of antitopoisomerase-I and anticentromere AAbs, it would be extremely valuable and highly recommended, to always have the test available for the detection of anti-ARNPol-III. Similarly, including this test into the design of clinical trials and into the follow-up protocols would be of critical importance for our patients.

References
[1]
C. Ferri, M. Sebastiani, A. Lo Monaco, M. Iudici, D. Giuggioli, F. Furini, et al.
Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients’ population and review of the literature.
Autoimmun Rev, 13 (2014), pp. 1026-1034
[2]
M. Satoh, M. Vazquez-Del Mercado, E.K. Chan.
Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.
Mod Rheumatol, 19 (2009), pp. 219-228
[3]
A. Mavropoulos, T. Simopoulou, A. Varna, C. Liaskos, C.G. Katsiari, D.P. Bogdanos, et al.
B regulatory cells are decreased and functionally impaired in patients with systemic sclerosis.
Arthritis Rheum, 68 (2016), pp. 494-504
[4]
M. Kuwana, K. Kimura, Y. Kawakami.
Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay.
Arthritis Rheum, 46 (2002), pp. 2742-2747
[5]
J. Parker, R. Burlingame, T. Webb, C. Bunn.
Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA.
Rheumatology, 47 (2008), pp. 976-979
[6]
M. Kuwana.
A To-Do List at Diagnosis of Systemic Sclerosis with Positive Anti-RNA Polymerase III Antibodies.
J Rheumatol, 44 (2017), pp. 550-552
[7]
V.D. Steen.
Autoantibodies in systemic sclerosis.
Semin Arthritis Rheum, 35 (2005), pp. 35-42
[8]
E.G. Wirz, V.K. Jaeger, Y. Allanore, G. Riemekasten, E. Hachulla, O. Distler, et al.
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.
Ann Rheum Dis, 75 (2016), pp. 1285-1292
[9]
M.G. Lazzaroni, I. Cavazzana, E. Colombo, R. Dobrota, J. Hernández, R. Hesselstrand, et al.
Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EUSTAR cohort and possible recommendations for screening.
J Rheumatol, 44 (2017), pp. 639-647
[10]
F. Van den Hoogen, D. Khanna, J. Fransen, S.R. Johnson, M. Baron, A. Tyndall, et al.
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.
Arthritis Rheum, 65 (2013), pp. 2734-2747

Please cite this article as: Hernández-Flórez D, Genaro Susan, Martínez-Barrio J, López-Longo FJ, Valor L. Hiperactivación del linfocito B y producción de los autoanticuerpos anticentrómero, antitopoisomerasa-I, anti-ARNPol-III en lafisiopatología de la esclerosis sistémica cutánea. Rev Colomb Reumatol. 2020;27:68–70.

Copyright © 2019. Asociación Colombiana de Reumatología
Article options
Tools
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.